Current efforts to circumvent BCC chemoresistance are focused on perturbing the oncogenic activity of GLI, either through directly inhibiting the GLI proteins or inhibiting the molecules that modulate GLI activity (23). The gene discussed is GLI1; the disease is skin basal cell carcinoma.